Back to search
FDAFDA · Food and drugs·Recall number D-0330-2021

Distributed by: DocRx, Methylprednisolone Tablets, USP 4 mg, Rx, 21 Count Blister, NDC: 69306-004-21, Relabeled by: Enovachem Pharmaceuticals 379 Van Ness Ave. Suite 1403-1406, Torrance, CA 90501, Manufactured by: Jubilant Cadista Pharmaceuticals Inc. Source NDC: 59746-001-03, DocRx, Mobile, AL 36608

Published April 21, 2021 · Recall initiated: March 19, 2021

Summary

FDA records drug Class III recall D-0330-2021, published April 21, 2021 and initiated March 19, 2021. Recalling firm: Asclemed USA Inc. dba Enovachem Pharmaceuticals; Status: Ongoing; Reported quantity: N/A; Lot: Lot #: 20K0043P, Exp. 8/31/2022; 20L0026P, Exp. 9/30/2022. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Illegible label: Manufacturer received complaint of mis-alignment print of the printed dosing instructions on the blister card.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Asclemed USA Inc. dba Enovachem Pharmaceuticals
Distributor
Distributed to three physicians in the following states: CA, LA (Enovachem). DocRx distributed recalled product to one Distributor located in AL.
Lot
Lot #: 20K0043P, Exp. 8/31/2022; 20L0026P, Exp. 9/30/2022
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Distributed by: DocRx, Methylprednisolone Tablets, USP 4 mg, Rx, 21 Count Blister, NDC: 69306-004-21, Relabeled by: Enovachem Pharmaceuticals 379 Van Ness Ave. Suite 1403-1406, Torrance, CA 90501, Manufactured by: Jubilant Cadista Pharmaceuticals Inc. Source NDC: 59746-001-03, DocRx, Mobile, AL 36608 recalled?

Yes. FDA published recall D-0330-2021 on April 21, 2021. Reported hazard: Labeling: Illegible label: Manufacturer received complaint of mis-alignment print of the printed dosing instructions on the blister card.

What should I do if I have this product?

Voluntary: Firm initiated · Letter